key: cord-0883454-rcwufnja
authors: McKinnon, JE; Wang, DD; Zervos, M; Saval, M; Marshall-Nightengale, L; Kilgore, P; Pabla, P; Szandzik, E; Maksimowicz-McKinnon, K; O'Neill, WW
title: Safety and Tolerability of Hydroxychloroquine in healthcare workers and first responders for the prevention of COVID-19: WHIP COVID-19 Study
date: 2021-12-23
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.12.343
sha: 4e3362a977e82477b1867e6032ec370133fd27cc
doc_id: 883454
cord_uid: rcwufnja

Background : Healthcare workers (HCW) are among the highest risk groups for acquisition of COVID-19 due to occupational exposures. The WHIP COVID-19 study aimed to evaluate the safety and efficacy of hydroxychloroquine (HCQ) as chemoprophylaxis for SARS-CoV-2 infection in this population. Methods : HCW, first responders and other occupationally high-risk participants were enrolled in a randomized, placebo-controlled clinical study of HCQ from April-October 2020. The trial compared daily versus weekly HCQ to placebo and to a prospective cohort on HCQ for autoimmune diseases. Participants were followed for 8 weeks. Serology or a positive PCR test were used to determine laboratory confirmed clinical cases. Results : 624 participants were randomized to placebo (n=200), weekly HCQ (n=201), daily HCQ (n=197). For the primary safety endpoint, 279 (44.7%) participants experienced AE level II or lower (total AEs n=589), similar rates in all randomized groups (p=0.188) with no hospitalizations or interventions required. Only 4 laboratory confirmed COVID-19 cases occurred, with 2 in the placebo arm and one in each HCQ randomized arm. Conclusions : This randomized placebo-controlled trial was able to demonstrate the safety of HCQ outpatient chemoprophylaxis in high-risk groups against COVID-19. Future studies of chemoprophylaxis for SARS-CoV-2 are needed as the epidemic continues worldwide.

In December 2019, a novel disease caused by a new virus now known as SARS-CoV-2, commonly referred to as coronavirus disease 2019 (COVID- 19) , was identified in Wuhan, China. (Huang et al., 2020) Since then, this deadly pandemic infection has spread worldwide with over 261 million cases and over 5 million deaths as of November, 2021), with observed case-fatality ratios ranging between 0.9% to 7.9% (Johns Hopkins Coronavirus Resource Center, https://coronavirus.jhu.edu/map.html). chloroquine are capable of binding to the human ACE-2 protein that serves as the CoV-2 viral receptor and interfere with the viral S protein's ability to bind to gangliosides. Initial studies on SARS-CoV-2 showed improved HCQ activity over CQ in-vitro with lower EC50 values for HCQ. Based on the available in-vitro and clinical data, HCQ was selected as chemoprophylaxis for persons at high risk for exposure to infected populations through their work environment including HCW and persons employed in other high-risk occupations in our study.

The study "Will Hydroxychloroquine Impede or Prevent COVID-19" (WHIP COVID-19 Study) was designed as a 3000-participant study of HCW, first responders and correctional/law officers (FR), nursing home workers (NHW), medical students (MS), public transit workers, and household family members of HCW in Michigan and Ohio. Eligible participants who were asymptomatic for prespecified signs and symptoms suggestive of COVID-19 infection were entered into the study.

The study was a randomized, placebo controlled, double blind study with 3 active randomized arms and a comparator HCQ cohort on maintenance full dose therapy for autoimmune disease (AD).

Participants were randomized in a 1:1:1 ratio to either oral dosing of HCQ 400mg weekly, HCQ 200mg daily after a loading dose of 400mg on day 1, or placebo daily. Only the unblinded pharmacist was aware of the randomized treatment assignment. Participants were provided 8-week packets of medications as per their randomization assignment. The non-randomized HCQ cohort was followed for 8 weeks and underwent study procedures and remained on their medications. The trial protocol, statistical analysis plan, and the de-identified trial data has been uploaded to Vivli Center for Global Clinical Research Data repository (https://doi.org/10.25934/00007320).

The study was approved by the Henry Ford Hospital (HFH) institutional review board on April 6 th , 2020, and the first participant was enrolled on April 10 th , 2020. The protocol was submitted for an investigational new drug application and received FDA approval (IND #149359) and was listed in ClinicalTrials.gov (N• NCT04341441). All participants completed an online volunteer pre-screening questionnaire form and if the participant qualified for study enrollment, an invitation to participate in the study was extended. Participants were contacted directly to complete symptom screening and informed consent process in person or electronically (consent process video and an online consent form). Verbal consent was also available for those participants not comfortable with the online process. A Data Safety Monitoring Board (DSMB) was established and reviewed the study progress and safety data monthly. The patient screening and allocation is detailed in the Consort Flow diagram (Graph 1).

Participants enrolled in the study were contacted by the study staff to review study questionnaires and concomitant medications and scheduled at their preferred participating clinical site for blood draws, symptom review, and evaluation. All participants were evaluated and had laboratory evaluations done at baseline (post-enrollment), week 4 and at week 8 of the study. Weekly symptom assessments were completed via telephone and/or electronic encounters (virtual visits, email), as preferred by the participant, to enhance adherence to the protocol. The weekly monitoring was designed to assess for the development of any adverse events (AE) defined as the following: COVID-19 related symptoms, COVID-19 clinical disease, and medication side effects. AE reporting used the common terminology criteria for AEs, grades (1) (2) (3) (4) (5) and reporting based on US DHHS and NIH guidelines (HHS.gov; NIH.gov).

Participants who reported symptoms suggestive of COVID-19 infection (2 or more symptoms as listed in the updated CDC list for April 27, 2020 which included: fever, cough, shortness of breath, chills, shaking chills, muscle pain, headache, sore throat and new loss of smell or taste) were referred for testing and evaluation by their primary care physician or local medical center. Participants determined to be positive for COVID-19 by either study or clinical testing completed the study at that timepoint.

Every effort to obtain confirmatory test results for COVID-19 were done, including patient self-report, at study evaluations if presenting with symptoms, and from supportive medical records or study testing. Participants diagnosed with COVID-19 were asked to present for a study visit to provide a blood sample and answer an end of study questionnaire within 30 days of recovery.

Samples were collected for SARS-CoV-2 serology assessments using a SARS-CoV-2 IgG assay from Beckman Coulter, Inc, Indianapolis, Indiana, USA and confirmed with the Elecsys Anti-SARS-CoV-2 assay from Roche Diagnostics, Rotkreuz, Switzerland. All tests were completed following the manufacturer's specifications and were done in the HFH clinical laboratory or at the HFH Infectious Diseases Research Laboratory. Testing for COVID-19 serologies were not completed in real time as the assays were not available at the time of study initiation. Sample testing for serology were done in batch and the initial serologic testing was completed November 2020.

For the study primary outcome, clinical COVID-19 disease was confirmed if the participant at any time during the study if the following was determined: a) Presentation with COVID-19 symptoms during study follow-up (defined as fever ≥38• C, or two or more non-fever symptoms that are new since baseline) and b) laboratory confirmation of SARS-CoV-2 infection (test positive) defined as at least one positive laboratory test (RT-PCR and/or IgM/IgG positive serology). The laboratory test results were obtained from (a) study blood samples (IgM and IgG serology), or (b) RT-PCR test results ordered by a participant's primary care physician, local testing center or through Employee Health.

Serology results were reviewed by 2 infectious disease specialists and adjudicated as negative, positive, or unknown/indeterminate. Baseline positive serology was defined as a participant having either a positive IgG, or positive IgM serology at baseline followed by IgG seroconversion at subsequent timepoints.

The study used intention to treat analysis to determine treatment efficacy based on patients who were SARS-CoV-2 negative at the baseline, as the study did not have reliable assays available for COVID-19 detection at the time of initial enrollment. The primary analysis compared the rate of COVID-19 disease for each treatment group to the placebo group with a Mantel-Haenszel chi-square test with multiplicity adjustment using the Dunnett's step up method. The stratifying variables were site, and high vs. low-risk groups. The high-risk group included HCW (including environmental service, NHW, and MS) who worked in COVID-19 care areas, emergency rooms (ER) and intensive care units caring for COVID-19 patients and household family members. Law enforcement, FR, public transit drivers and DDOT bus drivers were also designated as a high-risk group. Low-risk groups included HCW (including medical students) who work in non-COVID-19 patient-care areas without direct patient contact or in administrative roles.

The sample size was determined with one planned interim analysis when 50% of the participants had completed their 8 weeks of treatment using an O'Brien-Fleming alpha spending method to ensure an overall type 1 error of 0.05. With a sample size of 900 per group and alpha=0.0492, the power to detect a 32% reduction in COVID-19 disease rate (10% vs 6.8%) between the placebo group and each HCQ treated group was determined to be 87%. Based on the estimation of 5-10% of patients with SARS-CoV-2 infection present at baseline, the study required 1000 per group with a total of 3000 patients to complete the trial.

The DSMB and study chairs were provided weekly safety AE reports and convened monthly to review trial conduct and safety data. All AEs were noted including expected and unexpected events reported by participants and criteria for AE and severe AE (SAE) used standard definitions.

The trial had significant declines in study enrollment following the U.S. FDA revoke of the Emergency Use Authorization for Hydroxychloroquine on June 15 th , 2020 (Letter revoking EUA for chloroquine phosphate and hydroxychloroquine sulfate, 6/15/2020 (fda.gov)).(Food and Drug Administration, 2020) The EUA was revoked following several published articles suggesting possible increased risk for morbidity and mortality, most of which were subsequently retracted or disproven. DSMB determined the trial study doses were safe but due to low enrollment and low event numbers, it was recommended to be stopped early as the study endpoints would not be met. The WHIP COVID-19 study was terminated on December 14 th , 2020.

All 624 enrolled participants were used for the safety analyses and 578 participants had sufficient data for the efficacy analyses. 200 participants were randomized to the placebo arm, 201 to the 400mg HCQ weekly dose arm, 197 to the 200mg HCQ daily dose arm and 26 participants were enrolled that were taking HCQ for their AD treatment in the non-randomized control arm. The participants were mostly female (59%), high-risk group (69%), Caucasians (85%), with a mean age 44.9 years. Most participants were working in health care, primarily hospitals (84%) in the Detroit area, with the majority having direct patient contact (82%) and over half providing direct care to COVID-19 patients (54%). (Table 1 ) Sixty percent reported contact with a COVID-19 positive patient prior to study entry.

Of the 624 participants enrolled, only 279 (44.7%) experienced an AEs, with a total AEs reported during the study at 589 events. All study adverse events were level 1 or 2 in severity. No AE grade 3 or 4, or SAEs or visits to the ER or hospital occurred during the study. (Table 2) Grade 1 and 2 AEs in participants were equally distributed between the randomized groups with 85 participants in the placebo arm, 95 in the weekly HCQ arm and 97 in the daily HCQ arm (p=0.38).

The patients on full dose HCQ only reported 2 participants with AEs. The severity of the events was similar per randomized group between grade 1 and 2 (p=0.188).

The most common side effect reported was gastrointestinal (GI) disorders (e.g., nausea and gastrointestinal upset). GI symptoms were similarly distributed between randomized treatment arms with 52 AEs in the placebo arm, and 42 in HCQ weekly and 54 in the HCQ daily arm respectively.

Most AEs were grade 1. Similarly, nervous system disorders (primarily headaches) were equally distributed between groups. Cardiac disorders were only palpitations, mostly grade 1, without any patient requiring referral to the ER or hospital. No statistically significant differences in AEs distribution between groups was identified during the study at any timepoint.

During the clinical trial, 35 participants were considered unknown/indeterminate for COVID-19 status due to serologies not confirming positive seroconversion, clinical symptoms without a positive serology or PCR test or missing laboratories or visits to confirm COVID-19 infection. All patients suspected of COVID-19 infection were referred to their employee health or primary care providers for further evaluation and testing, and none required hospitalization. Four patients were confirmed positive by laboratory results (PCR or serology) during the study, with 3 participants also demonstrating clinical disease, which was the study primary endpoint. (Table 3) The placebo arm had 2 patients with positive laboratory testing with 1 with confirmed disease. The two randomized HCQ arms had one confirmed positive COVID-19 case each. No cases of COVID-19 or positive serologies were seen in the 25 patients who were chronically on HCQ. No statistically significant difference was seen between groups for positive serologies or confirmed COVID-19 cases due to low event numbers. (Table 4 ) Multiple imputation analyses also demonstrated p-values between 0.27 to 0.85 for COVID test positive results and 0.69 to 1.0 for confirmed COVID-19 disease analyses.

In our randomized, placebo-controlled trial for HCQ chemoprophylaxis using either daily or weekly dosing, we were able to demonstrate the safety of the HCQ outpatient regimen as compared with recent HCQ treatment review using the Cochrane review manager identified 19 treatment trials out of virologic cure (OR=2.08) and radiological cure (OR= 3.89), but no effect on mortality (aHR=1.05) in the symptomatic treatment settings. (Mittal et al., 2021) The WHIP COVID-19 Study was not able to demonstrate efficacy of the HCQ strategy as only 4 confirmed cases of COVID-19 were identified in the study, a key limitation to assess the strategy efficacy. The low event rate was due to previously mentioned concomitant factors that occurred during enrollment. Our study participants risk was significantly decreased in part by very aggressive masking and social distancing interventions initiated at our facilities early in the epidemic, impacting the positivity rate for COVID-19 in the HFH System, from which over 60% of our participant pool was derived. The interventions were considered to be highly effective. However, the study was able to demonstrate conclusively that no increased risk for AEs was seen between the HCQ treatment arms as compared to placebo. Due to limitations with study participants presenting in-person to the research or hospital settings during the pandemic, the participants could not be followed on-site and COVID-19 cases that may have been detected with more active in-person follow up and with real-time testing could have been missed. All symptomatic patients that were referred for testing and evaluation due to symptoms, but infrequently followed up for these assessments while none required hospitalization. Another limitation was lack of availability of accurate real-time assays to detect COVID-19 during the early period of the pandemic. Both assay availability and resource allocation of the available tests for clinical use prohibited potential real time testing of patients and case identification.

In summary, the WHIP COVID-19 Study was able to confirm that HCQ when administered in the outpatient setting for occupationally high-risk groups for COVID-19 infection is safe as either a daily or weekly dose. Meta-analyses and international studies have shown the value and safety of HCQ as a chemoprophylactic strategy. With the emergence of multiple SARS-CoV-2 variants and diminished effectiveness of currently available vaccines, chemoprophylaxis should be more fully evaluated as part of a comprehensive strategy to identify effective and safe regimens and interventions to be made available as new variants emerge and especially for the vulnerable populations for whom vaccine antibody response and protection will likely be weak or infection and clinical symptoms consistent with COVID-19 disease were included. P-value for the comparison between groups including the participants with † HCQ therapy for autoimmune diseases was 0.75.

Hydroxychloroquine for SARS CoV2 Prophylaxis in Healthcare Workers -A

Multicentric Cohort Study Assessing Effectiveness and Safety

Impact of Bamlanivimab Monoclonal Antibody Treatment on Hospitalization and Mortality Among Nonhospitalized Adults With Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Association Between COVID-19 and Myocarditis Using Hospital-Based Administrative Data -United States

A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19

Risk factors and frequency of COVID-19 among healthcare workers at a tertiary care centre in India: a case-control study

COVID-19 induced bradyarrhythmia and relative bradycardia: An overview

Effectiveness of Oseltamivir Prophylaxis in Influenza Outbreaks in Residential Aged Care

Food and Drug Administration (FDA) revoke the Emergency Use Autorization (EUA) for emergency use of oral formulations of chloroquine phosphate (CQ) and hydroxychloroquine sulfate (HCQ)

Cardiac Complications Attributed to Hydroxychloroquine: A systematic review of the Literature Pre-COVID-19

Benefit of early treatment with oseltamivir in hospitalized patients with documented 2009 influenza A (H1N1): retrospective cohort study

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Comparison of the antiviral activity in vitro of some non-steroidal anti-inflammatory drugs

In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine

Randomized Controlled Trials of Early Ambulatory Hydroxychloroquine in the Prevention of COVID-19 Infection, Hospitalization, and Death: Meta-Analysis

Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

Safety of Hydroxychloroquine among Outpatient Clinical Trial Participants for COVID-19

Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19

Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19)

Retraction-Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. The Lancet

Clinical Efficacy of Chloroquine derivatives in COVID-19 Infection: Comparative meta-analysis between the Big data and the real world

A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19

Systematic review and metaanalysis of efficacy and safety of hydroxychloroquine and chloroquine in the treatment of COVID-19

Hydroxychloroquine as Prophylaxis for COVID-19: A Review

Diaa El-Deen AM. Contemporary approach to understand and manage COVID-19-related arrhythmia. The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of

Risk of COVID-19 among frontline healthcare workers and the general community: a prospective cohort study

Oxford-led international research finds hydroxychloroquine safe in over 130,000 patients

Covid-19 and development of heart failure: mystery and truth

Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants

The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19

Hydroxychloroquine as Pre-exposure Prophylaxis for Coronavirus Disease

Clinical infectious diseases : an official publication of the Infectious Diseases Society of

Lancet gate: a matter of fact or a matter of concern

Hydroxychloroquine For Prophylaxis Of COVID-19 In Health Workers: A Randomized Clinical Trial

Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State

Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: An open-label randomized trial

Evolutionary trajectory of SARS-CoV-2 and emerging variants

Hydroxychloroquine and covid-19

Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 : A Randomized Trial

Neutralizing monoclonal antibodies for treatment of COVID-19

Effectiveness of SARS-CoV-2 mRNA Vaccines for Preventing Covid-19 Hospitalizations in the United States

Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape

Association Between Implementation of a Universal Face Mask Policy for Healthcare Workers in a Health Care System and SARS-CoV-2 Positivity Testing Rate in Healthcare Workers

Hydroxychloroquine-inhibited dengue virus is associated with host defense machinery

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

World Health Organization. WHO Living guideline: Drugs to prevent COVID-19; 2021

Consort Flow Diagram

We want to thank all the participants and all the hard-working personnel that made this study possible. We would like to thank the Public Health Sciences department for their work on setting up this study and in conducting all the analyses. Special thanks to L. Schultz, M. Lu and Dr. C. Johnson.We would also like to thank all the clinicians and investigators who advised or aided in the undertaking of this study.

This study was supported by internal funding from Henry Ford Health System, the Bill and Melinda Gates Foundation (Investment ID: INV-018560) and multiple philanthropic donations from donors in Michigan and the United States that supported the goal of COVID-19 prevention studies.

None of the investigators have potential conflicts of interest related to this manuscript.

Note: No Serious Adverse Events were recorded in any of the treatment groups. No Grade 3 or 4 adverse events were recorded in any of the treatment groups. Top 10 reported adverse event groups are listed above. All other AE disorders were less than 10 events total per group.